| Filed On | Filing |
|---|---|
| 26 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Forward Looking Statements This presentation contains “forward-looking statements” including, without limitation, statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefi... |
| 23 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 |
| 30 Sep 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., Director and 6 others
Received 70,000 shares by exercise or conversion ($195K) |
| 17 Sep 2026 |
Form 4: Thomas Stephen Basil, Director
Sold 100,000 shares ($1.37M) |
| 15 Sep 2026 | 144 |
| 03 Sep 2026 | 8-K: Regulation FD Disclosure |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | 8-K: Other Events |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 08 Jul 2026 | SCHEDULE 13G |
| 07 Jul 2026 | SCHEDULE 13D/A |
| 01 Jul 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., Director and 6 others
Granted 70,284 Stock Option (Right to Buy) |
| 01 Jul 2026 |
Form 4: Celebi Breanna Maurine, Director
Granted 70,284 Stock Option (Right to Buy) |
| 01 Jul 2026 |
Form 3: Celebi Breanna Maurine, Director
No securities owned |
| 01 Jul 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 30 Jun 2026 |
Form 4: Brennan Aoife, Director
Received 68,750 shares by exercise or conversion · Sold 30,902 shares ($407K) |
| 30 Jun 2026 | 144 |
| 12 Jun 2026 | 424B5 |
| 12 Jun 2026 | 8-K: Entry into a Material Definitive Agreement; Other Events |
Loading...
